Table 2.
Patient characteristic | Percent receiving curative therapy |
Black vs. White | ||||||
---|---|---|---|---|---|---|---|---|
Full sample a |
Black a |
White a |
||||||
N | % | N | % | N | % | P-value b | ||
Age | 67–69 | 15,493 | 77.2 | 1822 | 64.6 | 13,671 | 78.9 | <0.001 |
70–74 | 25,166 | 73.3 | 2510 | 63.9 | 22,656 | 74.4 | <0.001 | |
75–79 | 19,141 | 59.5 | 1692 | 48.5 | 17,449 | 60.5 | <0.001 | |
80–84 | 9017 | 34.8 | 699 | 25.5 | 8318 | 35.6 | <0.001 | |
Tumor risk | Low | 38,783 | 62.0 | 3464 | 54.7 | 35,329 | 62.7 | <0.001 |
Moderate | 30,024 | 69.6 | 3259 | 57.9 | 26,765 | 71.0 | <0.001 | |
Marital status | Married | 49,445 | 69.2 | 3725 | 61.2 | 45,720 | 69.9 | <0.001 |
Not married | 13,984 | 57.6 | 2479 | 51.4 | 11,505 | 58.9 | <0.001 | |
Unknown | 5388 | 49.1 | 519 | 43.9 | 4869 | 49.6 | 0.01 | |
Comorbidity | 0 | 37,081 | 67.6 | 3232 | 56.0 | 33,849 | 68.7 | <0.001 |
1,2 | 24,091 | 65.6 | 2390 | 59.6 | 21,701 | 66.2 | <0.001 | |
≥3 | 7645 | 53.4 | 1101 | 49.7 | 6544 | 54.0 | 0.008 | |
Income | Q1: <$35,528 | 17,458 | 57.7 | 3807 | 51.4 | 13,651 | 59.4 | <0.001 |
Q2: $35,528–<47,930 | 17,344 | 65.1 | 1520 | 59.9 | 15,824 | 65.6 | <0.001 | |
Q3: $47,930–<65,852 | 17,104 | 67.9 | 942 | 64.4 | 16,162 | 68.1 | 0.02 | |
Q4: >$65,852 | 16,911 | 70.7 | 454 | 66.3 | 16,457 | 70.9 | 0.04 | |
Life expectancy | <10 years | 47,708 | 60.6 | 4771 | 53.6 | 42,937 | 61.4 | <0.001 |
≥10 years | 21,109 | 75.9 | 1952 | 62.6 | 19,157 | 77.2 | <0.001 | |
Clinical benefit | Low c | 26,410 | 56.7 | 2445 | 51.9 | 23,965 | 57.2 | <0.001 |
Intermediate d | 33,681 | 68.4 | 3345 | 57.2 | 30,336 | 69.6 | <0.001 | |
High e | 8726 | 79.6 | 933 | 64.2 | 7793 | 81.4 | <0.001 | |
Overall | 68,817 | 65.3 | 6723 | 56.2 | 62,094 | 66.3 | <0.001 |
Chi-square test for receipt of curative therapy and each covariate: P<0.001 for all comparisons.
P-value is for chi-square test of whether receipt of curative therapy differs between black and white patients.
Low-benefit: low-risk tumors and life expectancy <10 years.
Intermediate-benefit: low-risk tumors and life expectancy ≥10 years or moderate-risk tumors and life expectancy <10 years.
High-benefit: moderate-risk tumors and life expectancy ≥10 years.